Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company UroGen Pharma Ltd.
DescriptionSustained release formulation of the chemotherapy agent Mitomycin C
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationBladder cancer
Indication DetailsTreat low-grade upper tract urothelial carcinoma (UTUC); Treat low-grade, non-muscle invasive upper tract urothelial carcinoma
Regulatory Designation U.S. - Orphan Drug (Treat low-grade upper tract urothelial carcinoma (UTUC))

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today